Emesis as a Complication of Cancer Chemotherapy: Pathophysiology, Importance, and Treatment | Zendy

Graves Terri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Emesis as a Complication of Cancer Chemotherapy: Pathophysiology, Importance, and Treatment

Author(s) -

Graves Terri

Publication year - 1992

Publication title -

pharmacotherapy: the journal of human pharmacology and drug therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.227

H-Index - 109

eISSN - 1875-9114

pISSN - 0277-0008

DOI - 10.1002/j.1875-9114.1992.tb04469.x

Subject(s) - ondansetron , medicine , nausea , vomiting , chemotherapy , cancer chemotherapy , intensive care medicine , complication , anesthesia

Up to 30% of patients receiving chemotherapy experience uncontrolled nausea and vomiting despite pharmacotherapeutic advances. Currently marketed agents used to treat these symptoms are compared. Dose escalation of these agents may improve response rates. Recent focus has been on a new class of antiemetics, the serotonin antagonists. Ondansetron, currently the only serotonin antagonist with Food and Drug Administration approval for treatment of chemotherapy‐induced emesis, demonstrates the efficacy and potential advantages of this class of antiemetics.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research